Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments
Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world.
Switch from selling COVID-19 drugs on market rather than to governments continues to sting at Pfizer
Pfizerโs forecast for sales of its COVID-19 vaccine and treatment next year falls more than $5 billion short of the Wall Street consensus.
Company bosses and workers grapple with the fallout of speaking up about the Israel-Hamas war
The fallout from the Israel-Hamas war has spilled into workplaces everywhere, with corporate leaders from the highest ranks of prominent companies weighing in with their views while workers complain their voices are not being heard.
In venue fit for head of state, Japan PM seeks Pfizer doses
Japanโs prime minister met with Pfizerโs CEO in an unusually high-profile setting to make sure the drugmaker would deliver COVID-19 vaccine it has promised to the nation.
President Biden memorializes half-million American lives lost to COVID-19
I know what itโs like to not be there when it happens," said Biden, who has long addressed grief more powerfully than perhaps any other American public figure. AdAfter he spoke, the president along with first lady Jill Biden, Vice President Kamala Harris and her husband Doug Emhoff stood outside the White House for a moment of silence at sundown. In one of his many symbolic breaks with his predecessor, Biden has not shied away from offering remembrances for the lives lost to the virus. The COVID-19 death total in the United States had just crossed 400,000 when Biden took the oath of office. The administration says it expects to have enough vaccine available for every American by the end of July.
The Latest: Young S. Koreans taking crucial university exam
The Education Ministry says about 493,430 students began taking the one-day test at about 1,380 test sites across South Korea on Thursday. The university from which a South Korean graduates significantly affects job prospects, social standings and even marriage partners. Health care workers, citizens above 65 and people living in care homes will be the first groups to be vaccinated. Redfield says earlier surges in COVID-19 illnesses were concentrated in one area of the country or another, and health care workers and equipment could be shifted from one place to another to deal with it. ___TORONTO โ Canadaโs health minister says health officials will soon complete a review of the coronavirus vaccine made by Pfizer and BioNTech.
Pfizer tops 3Q earnings views, makes progress on COVID shot
Pfizer executives had expected data from their 44,000-person international study would show by Oct. 31 how well it prevents coronavirus infections. Analysts peppered Bourla and other Pfizer executives with so many questions about the study that he repeatedly asked for their patience. It expects revenue of $48.8 billion to $49.5 billion, narrowed from its previous forecast of $48.6 billion to $50.6 billion. Pfizer will receive about $12 billion in return and its shareholders will get roughly one Viatris share for each Pfizer share they own. Pfizer expects to be able to grow revenue at least 6% annually through 2025 as a result of the transformation.
Pfizer: Mid-November earliest it can seek virus vaccine OK
NEW YORK โ Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and thatโs if everything goes well, the companyโs CEO announced Friday. Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25. Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his companyโs vaccine actually protects against the coronavirus. The vaccine made by Pfizer and its German partner BioNTech are among several leading candidates in final testing. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Instituteโs Department of Science Education.
Pfizer CEO pushes back against Trump claim on vaccine timing
Despite top U.S. federal health officials repeatedly stating that a vaccine is unlikely to be available widely until mid-2021, President Donald Trump has insisted that a vaccine will be ready before Election Day. โIโve spoken to Pfizer, Iโve spoken to all of the people that you have to speak to, Moderna, Johnson & Johnson, and others. โItโs become very political.โโWeโre weeks away from a vaccine,โ Trump added. Johnson & Johnson just started the final study of its vaccine last week. ___Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Instituteโs Department of Science Education.